[18F]Flotufolastat PET视觉RECIP在多西他赛治疗的转移性前列腺癌中的预后价值
本研究纳入69例接受紫杉类化疗的转移性前列腺癌患者,基线与随访行[18F]flotufolastat PET/CT,用视觉RECIP 1.0分为进展性疾病(PD)与非PD。PD组中位总生存12个月,非PD组45个月,RECIP的Harrell一致性指数0.84高于生化反应0.66。结论认为视觉RECIP评估具有高预后价值。
要点
- 视觉RECIP 1.0评估为PD者中位OS 12个月,非PD者45个月。
- RECIP的Harrell一致性指数0.84,高于生化反应的0.66。
- 视觉RECIP可用于紫杉类化疗转移性前列腺癌的预后分层。
核心结论
- 视觉RECIP评估的[18F]flotufolastat PET在紫杉类化疗的转移性前列腺癌患者中具有高预后价值。
研究设计与样本
- 纳入69例接受紫杉类化疗并具有基线与随访[18F]flotufolastat PET/CT扫描的转移性前列腺癌患者。
- 影像学反应采用视觉RECIP 1.0二分法分为进展性疾病(PD)与非PD。
- 生化反应定义为前列腺特异性抗原下降大于50%(去势抵抗)或降至小于0.2 ng/mL(激素敏感)。
- 采用Kaplan-Meier分析总生存,并计算Harrell一致性指数。
主要发现
- PD组中位总生存为12个月(95% CI,8.3个月至未达到),非PD组为45个月(95% CI,37个月至未达到)。
- RECIP的Harrell一致性指数为0.84(95% CI,0.72-0.97;P < 0.001)。
- 生化反应的Harrell一致性指数为0.66(95% CI,0.49-0.84;P = 0.07)。
关键数值与推荐
- 影像学反应采用视觉RECIP 1.0二分法分为PD与非PD。
- 生化反应定义为PSA下降大于50%(去势抵抗)或降至小于0.2 ng/mL(激素敏感)。
- PD组中位OS 12个月(95% CI,8.3个月至未达到),非PD组45个月(95% CI,37个月至未达到)。
- RECIP的Harrell一致性指数0.84(95% CI,0.72-0.97;P < 0.001),生化反应0.66(95% CI,0.49-0.84;P = 0.07)。
临床怎么用
- 对接受紫杉类化疗的转移性前列腺癌患者,可用[18F]flotufolastat PET视觉RECIP评估反应并以PD与否进行预后分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We aimed to assess the prognostic value of [18F]flotufolastat PET in patients with metastatic prostate cancer during taxane-based chemotherapy (CTx). Methods: In total, 69 patients who received CTx as well as baseline and follow-up [18F]flotufolastat PET/CT scans were included. Imaging response was assessed by visual RECIP 1.0 dichotomized into progressive disease (PD) and non-PD. Biochemical response was defined as a prostate-specific antigen decrease of greater than 50% (castration-resistant) or a decline to less than 0.2 ng/mL (hormone-sensitive). Kaplan-Meier analysis was performed regarding overall survival, and the Harrell concordance index was calculated. Results: Patients with PD showed a significantly shorter median overall survival of 12 mo (95% CI, 8.3 mo to not reached) compared with non-PD (45 mo; 95% CI, 37 mo to not reached). The Harrell concordance index for RECIP (0.84; 95% CI, 0.72-0.97; P < 0.001) was higher than biochemical response (0.66; 95% CI, 0.49-0.84; P = 0.07). Conclusion: [18F]flotufolastat PET assessed using visual RECIP has high prognostic utility in patients with metastatic prostate cancer undergoing CTx.
引用
- Kirchhoff S, Erber B, Rauscher I, et al. Prognostic Value of [18F]Flotufolastat PET Using Visual RECIP in Docetaxel-Treated Metastatic Prostate Cancer. J Nucl Med. 2026. PMID: 42020147. doi:10.2967/jnumed.125.271488
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。